Abstract
Lung cancer accounts for the highest incidence of cancer mortality worldwide. The EML4-ALK chromosomal rearrangement is involved in 2-7% of lung cancer cases. Crizotinib, the first-line treatment for ALK+ lung cancer is an effective treatment, however, resistance develops usually after one year. To prevent/overcome resistance, novel strategies are being explored.
Epidemiological studies show a reduction in the risk of cancer with the use of a hypoglycemic agent, metformin. We aimed to test a combination of metformin and crizotinib for toxicity and efficacy in a xenograft model of lung cancer.